Inhibition of NOS-2 induction in LPS-stimulated J774.2 cells by 1, 5-isoquinolinediol, an inhibitor of PARP

Journal of Physiology and Pharmacology

Volumn 57, Issue 1, 2006, Pages 109-117

  Olszanecki, R ^a,b   Gebska A ^a   Jawien J ^a   Jakubowski, A ^a   Korbut, R ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Department of Pharmacology ^*  (Poland)

Author keywords

1,5 isoqinolinediol; Inducible NOS; Lipopolysaccharide (LPS); Macrophages; PARP inhibitors

Indexed keywords

1,5 ISOQUINOLINEDIOL; 3 AMINOBENZAMIDE; CATALASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOQUINOLINE DERIVATIVE; LIPOPOLYSACCHARIDE; MANGANESE (III) TETRAKIS (4 BENZOIC ACID)PORPHYRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRITE; PORPHYRIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL LINE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; IC 50; MACROPHAGE; NONHUMAN; PROTEIN INDUCTION; RAT;

ANIMALS; BENZAMIDES; CELL LINE; CELL RESPIRATION; ENZYME INHIBITORS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; POLY(ADP-RIBOSE) POLYMERASES; QUINOLINES;

EID: 33645562515     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26(8):882-893.
2. Ueda K, Ogata N, Kawaichi M, Inada S, Hayaishi O. ADP-ribosylation reactions. Curr Top Cell Regul 1982; 21:175-187.
3. Beneke S, Burkle A. Poly(ADP-ribosyl)ation, PARP, and aging. Sci Aging Knowledge Environ 2004; 2004(49):re9.
4. Diefenbach J, Burkle A. Introduction to poly(ADP-ribose) metabolism. Cell Mol Life Sci 2005; 62:721-730.
5. Kun E, Bauer PI. Cell biological functions of PARP I: an overview. Ital J Biochem 2001; 50:15-18.
6. Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 2002; 59:1534-1553.
7. Chiarugi A. Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci 2002; 23:122-129.
8. Koh DW, Dawson TM, Dawson VL. Poly(ADP-ribosyl)ation regulation of life and death in the nervous system. Cell Mol Life Sci 2005; 62:760-768.
9. Erdelyi K, Bakondi E, Gergely P, Szabo C, Virag L. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation. Cell Mol Life Sci 2005; 62:751-759.
10. Cuzzocrea S. Shock, inflammation and PARP. Pharmacol Res 2005; 52:72-82.
11. Evgenov OV, Liaudet L. Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock. Curr Vasc Pharmacol 2005; 3:293-299.
12. Virag L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr Vasc Pharmacol 2005; 3:209-214.
13. Skaper SD. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection. Ann N Y Acad Sci 2003; 993:217-228.
14. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005; 31:603-617.
15. Bryant HE, Helleday T. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans 2004; 32(Pt 6):959-961.
16. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005; 52:109-118.
17. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005; 4:421-440.
18. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54:375-429.
19. Lirk P, Hoffmann G, Rieder J. Inducible nitric oxide synthase - time for reappraisal. Curr Drug Targets Inflamm Allergy 2002; 1:89-108.
20. Rumi G, Tsubouchi R, Nishio H, Kato S, Mozsik G, Takeuchi K. Dual role of endogenous nitric oxide in development of dextran sodium sulfate-induced colitis in rats. J Physiol Pharmacol 2004; 55:823-836.
21. Gebska A, Olszanecki R, Korbut R. Endotoxaemia in rats: role of leukocyte sequestration in rapid pulmonary nitric oxide synthase-2 expression. J Physiol Pharmacol 2005; 56:299-311.
22. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res 2002; 12:311-320.
23. Korhonen R, Lahti A, Kankaanranta H, Moilanen E. Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 2005; 4:471-479.
24. Dedon PC, Tannenbaum SR. Reactive nitrogen species in the chemical biology of inflammation. Arch Biochem Biophys 2004; 423:12-22.
25. Szabo C, Virag L, Cuzzocrea S, Scott GS, Hake P, O'Connor MP et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci U S A 1998; 95:3867-3872.
26. Le Page C, Sanceau J, Drapier JC, Wietzerbin J. Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation. Biochem Biophys Res Commun 1998; 243:451-457.
27. Banasik M, Ueda K. Inhibitors and activators of ADP-ribosylation reactions. Mol Cell Biochem 1994; 138:185-197.
28. Southan GJ, Szabo C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 2003; 10:321-340.
29. Li F, Drel VR, Szabo C, Stevens MJ, Obrosova IG. Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 2005; 54:1514-1522.
30. Olszanecki R, Gebska A, Kozlovski VI, Gryglewski RJ. Flavonoids and nitric oxide synthase. J Physiol Pharmacol 2002; 53(4 Pt 1):571-584.
31. Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995; 114:1335-1342.
32. Szabo C, Mitchell JA, Gross SS, Thiemermann C, Vane JR. Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysaccharide. J Pharmacol Exp Ther 1993; 265:674-680.
33. Wu CC, Thiemermann C, Vane JR. Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat. Br J Pharmacol 1995; 114:1273-1281.
34. Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res 1999; 43:509-520.
35. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15:323-350.
36. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999; 18:4446-4454.
37. Han YJ, Kwon YG, Chung HT, Lee SK, Simmons RL, Billiar TR et al. Antioxidant enzymes suppress nitric oxide production through the inhibition of NF-kappa B activation: role of H(2)O(2) and nitric oxide in inducible nitric oxide synthase expression in macrophages. Nitric Oxide 2001; 5:504-513.
38. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P et al. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med 2004; 14:55-64.
39. Obrosova IG, Julius UA. Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy. Curr Vasc Pharmacol 2005; 3:267-283.
40. Bojunga J, Dresar-Mayert B, Usadel KH, Kusterer K, Zeuzem S. Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats. Biochem Biophys Res Commun 2004; 316:771-780.